文献速递流行病学与生物统计

21世纪全球炎症性肠病的发病率和患病率:基于人群研究的系统综述

Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies.
PubMed 文献 · Lancet · 2017-10-16

该系统综述检索MEDLINE和Embase至2016年12月31日,纳入147项基于人群的观察性研究(119项发病率研究、69项患病率研究),评估全球克罗恩病和溃疡性结肠炎的发病率和患病率变化。欧洲和北美患病率最高,北美、大洋洲和欧洲许多国家炎症性肠病患病率超过0.3%;北美和欧洲多数研究显示发病率稳定或下降,而非洲、亚洲和南美新工业化国家发病率自1990年以来上升。

要点

  • 欧洲和北美炎症性肠病患病率最高,北美、大洋洲和欧洲许多国家超过0.3%。
  • 北美和欧洲22项克罗恩病研究中16项(72.7%)、18项溃疡性结肠炎研究中15项(83.3%)报告发病率稳定或下降。
  • 非洲、亚洲和南美新工业化国家发病率自1990年以来上升,如巴西克罗恩病APC +11.1%、溃疡性结肠炎APC +14.9%。

核心结论

  • 21世纪之交,炎症性肠病已成为全球性疾病,在社会日益西方化的新工业化国家发病率加速上升。
  • 西方国家发病率虽趋于稳定,但患病率超过0.3%,疾病负担仍高。
  • 这些数据凸显了研究炎症性肠病预防以及创新卫生保健系统以管理这一复杂且昂贵疾病的必要性。

研究设计与样本

  • 系统综述,检索MEDLINE和Embase至2016年12月31日,纳入1990年及以后报告克罗恩病或溃疡性结肠炎发病率或患病率的观察性、基于人群研究。
  • 基于人群定义为涉及特定区域内所有居民且患者代表该区域;要求溃疡性结肠炎和克罗恩病分别报告。
  • 排除未报告原始数据的研究以及仅报告儿童期发病(诊断年龄<16岁)炎症性肠病发病率或患病率的研究。
  • 最终纳入147项研究,包括119项发病率研究和69项患病率研究。

主要发现

  • 最高患病率报告于欧洲(溃疡性结肠炎:挪威505/10万;克罗恩病:德国322/10万)和北美(溃疡性结肠炎:美国286/10万;克罗恩病:加拿大319/10万)。
  • 北美、大洋洲和欧洲许多国家炎症性肠病患病率超过0.3%。
  • 北美和欧洲22项克罗恩病研究中16项(72.7%)、18项溃疡性结肠炎研究中15项(83.3%)报告发病率稳定或下降。
  • 自1990年以来,非洲、亚洲和南美新工业化国家发病率上升,包括巴西(克罗恩病APC +11.1% [95% CI 4.8-17.8],溃疡性结肠炎APC +14.9% [10.4-19.6])和台湾(克罗恩病APC +4.0% [1.0-7.1],溃疡性结肠炎APC +4.8% [1.8-8.0])。

关键数值与推荐

  • 欧洲最高患病率:溃疡性结肠炎挪威505/10万,克罗恩病德国322/10万。
  • 北美最高患病率:溃疡性结肠炎美国286/10万,克罗恩病加拿大319/10万。
  • 北美、大洋洲和欧洲许多国家炎症性肠病患病率超过0.3%。
  • 巴西克罗恩病APC +11.1%(95% CI 4.8-17.8),溃疡性结肠炎APC +14.9%(95% CI 10.4-19.6)。
  • 台湾克罗恩病APC +4.0%(95% CI 1.0-7.1),溃疡性结肠炎APC +4.8%(95% CI 1.8-8.0)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inflammatory bowel disease is a global disease in the 21st century. We aimed to assess the changing incidence and prevalence of inflammatory bowel disease around the world. METHODS: We searched MEDLINE and Embase up to and including Dec 31, 2016, to identify observational, population-based studies reporting the incidence or prevalence of Crohn's disease or ulcerative colitis from 1990 or later. A study was regarded as population-based if it involved all residents within a specific area and the patients were representative of that area. To be included in the systematic review, ulcerative colitis and Crohn's disease needed to be reported separately. Studies that did not report original data and studies that reported only the incidence or prevalence of paediatric-onset inflammatory bowel disease (diagnosis at age <16 years) were excluded. We created choropleth maps for the incidence (119 studies) and prevalence (69 studies) of Crohn's disease and ulcerative colitis. We used temporal trend analyses to report changes as an annual percentage change (APC) with 95% CI. FINDINGS: We identified 147 studies that were eligible for final inclusion in the systematic review, including 119 studies of incidence and 69 studies of prevalence. The highest reported prevalence values were in Europe (ulcerative colitis 505 per 100 000 in Norway; Crohn's disease 322 per 100 000 in Germany) and North America (ulcerative colitis 286 per 100 000 in the USA; Crohn's disease 319 per 100 000 in Canada). The prevalence of inflammatory bowel disease exceeded 0·3% in North America, Oceania, and many countries in Europe. Overall, 16 (72·7%) of 22 studies on Crohn's disease and 15 (83·3%) of 18 studies on ulcerative colitis reported stable or decreasing incidence of inflammatory bowel disease in North America and Europe. Since 1990, incidence has been rising in newly industrialised countries in Africa, Asia, and South America, including Brazil (APC for Crohn's disease +11·1% [95% CI 4·8-17·8] and APC for ulcerative colitis +14·9% [10·4-19·6]) and Taiwan (APC for Crohn's disease +4·0% [1·0-7·1] and APC for ulcerative colitis +4·8% [1·8-8·0]). INTERPRETATION: At the turn of the 21st century, inflammatory bowel disease has become a global disease with accelerating incidence in newly industrialised countries whose societies have become more westernised. Although incidence is stabilising in western countries, burden remains high as prevalence surpasses 0·3%. These data highlight the need for research into prevention of inflammatory bowel disease and innovations in health-care systems to manage this complex and costly disease. FUNDING: None.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017. PMID: 29050646. doi:10.1016/S0140-6736(17)32448-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。